The Supervisory Board of Fresenius Medical (FMS) Care has appointed Charles Hugh-Jones, MD, FRCP as a member of the Management Board, effective January 1, 2026. Hugh-Jones will serve as Global Chief Medical Officer. Hugh-Jones will succeed Franklin Maddux, MD as part of a planned transition after Maddux informed the Supervisory Board of his intention to retire. Hugh-Jones most recently served as CEO of Volastra Therapeutics from its inception as a discovery-stage startup to a clinical-stage biotech company, advancing novel oncology assets.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical price target lowered to EUR 37.40 from EUR 41.50 at JPMorgan
- Fresenius Medical Care Issues €500 Million Bond to Strengthen Financial Position
- Fresenius Medical price target lowered to EUR 39 from EUR 41 at Morgan Stanley
- Fresenius Medical Care Reports Strong Q3 2025 Growth
- Fresenius Medical Care Reports Strong Q3 Earnings